Aptorum Group Limited (APM)

Market Cap	9.03M
Revenue (ttm)	1.30M
Net Income (ttm)	-9.80M
Shares Out	4.17M
EPS (ttm)	-2.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,382
Open	2.50
Previous Close	2.43
Day's Range	2.17 - 2.50
52-Week Range	1.72 - 13.00
Beta	-0.09
Analysts	Strong Buy
Price Target	80.00 (+3,595.15%)
Earnings Date	Oct 3, 2023

About APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 18, 2018
• Employees: 18
• Stock Exchange: NASDAQ
• Ticker Symbol: APM

Financial Performance

In 2022, Aptorum Group's revenue was $1.30 million, a decrease of -15.95% compared to the previous year's $1.54 million. Losses were -$9.80 million, -60.88% less than in 2021.

Analyst Forecast

According to one analyst, the rating for APM stock is "Strong Buy" and the 12-month stock price forecast is $80.0.

Price Target

$80.0

(3,595.15% upside)

Analyst Consensus: Strong Buy